This assumption is supported by the fact that patients with dedifferentiated liposarcoma characteristically carry MDM2 (and CDK4/6) amplifications (Binh et al. 2005) and novel MDM2 inhibitors are tested in the first-line setting (NCT05218499). This evidence concerns the gene MDM2 and liposarcoma.